A Phase I study of Everolimus and Bendamustine in Patients with relapsed/refractory lymphoid hematologic malignancies
ConclusionThe combination of everolimus and bendamustine appeared to be well-tolerated and relatively efficacious.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Hematology | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Study | Thrombocytopenia | Treanda